Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3.
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018.
The approved recommended dosage of ILUMYA is a subcutaneous injection of 100mg at weeks 0, 4, and every 12 weeks thereafter 7.
A study was performed on the pharmacokinetics of this drug on various ethnicities.
The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5.
Applications:Suitable for use in ELISA and SDS-PAGE.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
抗体種類：Mab
宿主：human
Grade：Highly Purified
Purity：≥95%
Form：Supplied as a liquid in PBS, pH 7.5.
Specificity：Recognizes Tildrakizumab (IL23A).
Isotype：IgG1,k
Calc Applications Abbrev：E
Immunogen：Recombinant protein corresponding to humanized IL23A [Homo sapiens], expressed in CHO cells.
